AI for Pitch Books: Claude Tools for Investment Banking Presentations

Pitch Book Preparation and AI

Investment banking pitch books are the cornerstone of client development — from general coverage presentations (GP) to sell-side M&A, IPO, and financing pitches. Every pitch requires original market analysis, fresh comparable company data, updated precedent transactions, and a custom valuation model tailored to the client. Bankers spend enormous time synthesizing market data, building comps, and drafting narrative. Claude with ClaudeFinanceLab accelerates pitch book research, analysis, and structure — letting bankers focus on relationship and deal judgment rather than data assembly.

Market Overview Slide Research

• "Healthcare IT sector overview for GP pitch to mid-size HIT company: analyze the sector narrative for a pitch book page. Key themes: (1) Market size — US healthcare IT market $88B (2025), growing at 14.2% CAGR to $182B by 2030 (CAGR driven by EHR adoption, interoperability mandates, value-based care); (2) M&A environment — 2024-2025 deal volume $32B across 180 transactions; average EBITDA multiple 18-22x; strategic buyers (Epic, Oracle Health, Veeva) active alongside PE (Blackstone, Francisco Partners); (3) Key drivers — CMS interoperability rules, 21st Century Cures Act, AI/ML clinical decision support adoption; (4) Valuation landscape — high-growth HIT SaaS companies trading at 6-12x revenue vs mature IT services companies at 12-16x EBITDA. Summarize in 5 concise bullet points suitable for a slide."
• "Industry consolidation narrative for pitch: the industrial distribution sector has seen accelerating consolidation as national distributors (Grainger, Fastenal, MSC Industrial) gain scale advantages over regional players. Key consolidation drivers: (1) Purchasing leverage — large distributors negotiate 8-15% better pricing from manufacturers; (2) Digital investment — mid-market players cannot afford $50M+ e-commerce/ERP platforms needed to compete; (3) Cross-selling — national players can offer broader SKU coverage (200K+ SKUs vs 20-40K for regional) reducing customer switching; (4) Working capital — national players get 60-90 day payables vs regional 30 days. Tell the narrative of why our client (regional distributor $240M revenue) is an attractive M&A candidate or should consider acquiring smaller competitors."

Comparable Company Analysis

• "Comparable company table construction: I'm building comps for a SaaS company pitch. Our client: $48M ARR, 32% growth, 78% gross margin, ($12M) EBITDA (growing but not profitable). Comps universe: Veeva Systems, Procore Technologies, nCino, Blend Labs, Clearwater Analytics, Enfusion. For each comp, I need: Market cap, Enterprise value, EV/NTM Revenue multiple, EV/NTM EBITDA multiple, NTM Revenue growth %, Gross margin %. Using current market data structure: format as a comp table with median and mean. Then apply to our client: at median EV/NTM Revenue of 8.2x and NTM revenue of $58M (48M × 1.21), implied EV = $475M. Discuss key differences: our client smaller scale (penalized 1-2x turns) but faster growth (premium 1-2x turns) vs median 22% growth."
• "Selecting and benchmarking comps: company is a specialty chemicals manufacturer with $480M revenue, 19% EBITDA margin. Comp universe criteria: specialty chemicals (not commodity), $100M-$2B revenue, US listed. Potential comps: Innospec, Quaker Houghton, Balchem, Cabot Microelectronics (CMC Materials), Sensient Technologies, Stepan. Screen out: commodity chemical companies (Dow, LyondellBasell — different business model). For remaining comps, key multiples: EV/EBITDA range 8x-16x with median 11.5x; EV/Sales 1.0x-2.4x. Benchmark our client's 19% margin vs comps: if comps average 16% margin and trade at 11.5x, our client's superior margins justify premium → 13-14x EBITDA → EV range $1.18B-$1.27B."

Precedent Transaction Analysis

• "Precedent transaction comps table: researching sell-side M&A precedents in healthcare services for a pitch. Target profile: behavioral health, $150M revenue, 22% EBITDA margin, PE seller. Recent relevant precedents: (1) Acadia Healthcare / US Behavioral Health ($800M, 12.4x EBITDA, 2024); (2) BrightSpring Health / PE acquired add-on ($230M, 10.8x EBITDA, 2024); (3) Vertex Healthcare / strategic ($185M, 13.1x EBITDA, 2023); (4) Discovery Behavioral Health / private 10.2x (2023); (5) Springstone / KKR 11.8x (2022). Median: 11.8x EBITDA. Strategic buyers paid median 13.1x vs PE paid 10.5x. Apply to our client: $150M × 22% = $33M EBITDA × 11.8x = $389M; at strategic premium 13.1x = $433M. Control premium: add 20-35% premium for 100% acquisition."
• "Precedent transaction narrative: why is the current deal environment favorable? Factors: (1) Interest rate environment — rates declining from 5.25% peak to 4.5% improving LBO financing economics (10bps decline = ~5% increase in sponsor capacity per deal); (2) Corporate balance sheets — IG companies sitting on $1.8T in cash seeking growth M&A; (3) Backlog of PE exits — PE sponsors held assets 5+ years on average as IPO window was closed 2022-2024, now need liquidity; (4) Antitrust environment — DoJ/FTC stance moderating from 2022-2023 peak; (5) Multiple compression bottomed — strategic buyers seeing window to acquire growth at reasonable multiples before expansion. Our sector (healthcare IT) at 18-22x EBITDA vs 2021 peak 28-35x — still attractive historically."

Valuation Football Field

• "Football field chart data: building valuation range summary for M&A pitch. Company: $240M revenue, $48M EBITDA, $36M FCF. Methodologies: (1) EV/EBITDA comps: 10x-13x EBITDA ($480M-$624M EV); (2) EV/Revenue comps: 2.0x-2.6x revenue ($480M-$624M EV); (3) Precedent transactions: 11.5x-14.5x EBITDA ($552M-$696M EV — control premium included); (4) DCF: WACC 10.5%-11.5%, terminal growth 2.5%-3.0%, range $510M-$650M EV; (5) LBO analysis: at 6.0x entry leverage, sponsor target 18-20% IRR, 5-year hold, 3% revenue growth → supports $420M-$480M enterprise value (floor for PE buyers). Summarize in a ranked football field: LBO $420-480M (floor), Comps $480-624M, DCF $510-650M, Precedents $552-696M. Implied offer price recommendation: $580-640M (8% premium to comp midpoint, within precedent range)."

Executive Summary and Deal Narrative

• "Executive summary page structure: 1-page summary for sell-side M&A pitch. Structure: (1) Transaction overview — brief description of what we're recommending (full sale, partial sale, strategic partnership). (2) Key investment highlights (5 bullets): market leadership in X, recurring revenue X%, margin expansion trajectory, platform for geographic expansion, technology differentiation. (3) Transaction rationale — why now is the right time to transact (market dynamics, company performance inflection, buyer universe active). (4) Process overview — proposed timeline, confidentiality, buyer outreach. (5) Indicative valuation range — $X-$Y enterprise value. Draft this for a regional specialty insurer ($80M premiums, 14% ROE, niche workers' comp book with minimal catastrophe exposure)."
• "Situational pitch — fairness opinion support: our board is being asked to evaluate an unsolicited offer of $42/share vs current trading price of $36. Pitch book page needed: 'Board Considerations.' Elements: (1) Premium analysis — $42 represents 16.7% premium to unaffected 30-day VWAP ($36). Comp premiums for hostile/unsolicited: 25-35% average. Insufficient premium argument? (2) Intrinsic value — DCF implies $44-$52/share. Board has fiduciary duty to consider DCF, not just market price. (3) Strategic alternatives — have all strategic alternatives been explored? Is there a higher bidder? Board should run process. (4) Timing — offer comes after share price weakness from macro headwinds (not company-specific). (5) Recommendation: engage but not accept; seek $48-50/share. Argue for 45-day go-shop period to identify higher bidder."

Related Articles

• Mergers & Acquisitions AI
• Financial Due Diligence AI
• LBO Modeling AI